- Company-specific news, including clinical trial results, earnings reports, and corporate actions, drove significant stock declines across the market.
- The biotechnology and consumer-tech sectors experienced the sharpest downturns, with several firms seeing substantial share price drops.
- Abivax S.A. (NASDAQ: ABVX) led the losses, with its stock dropping over 44.10% due to concerns over clinical trial results.
The market saw significant declines today, led by biotechnology firms and a consumer-tech company. The downturn for Abivax S.A. (NASDAQ: ABVX), Oddity Tech Ltd. (NASDAQ: ODD), Celcuity Inc. (NASDAQ: CELC), and Praxis Precision Medicines, Inc. (NASDAQ: PRAX) was driven by company-specific news. These events ranged from clinical trial results and earnings reports to corporate stock decisions, causing investors to sell off shares.
Abivax S.A. experienced the sharpest fall, with its stock dropping 44.10% to close at $72.50. The stock traded between $69.81 and $83.34. The decline follows reports of cancer cases in a major trial for its lead drug, obefazimod. This news created new uncertainty about the drug’s future.
Oddity Tech Ltd. shares fell 29.61% to $9.84 after a major sell-off following its earnings report. The stock, which is now down about 87% over the last year, hit a daily low of $9.38. Oddity Tech Ltd. is a consumer-tech company that builds digital brands in the beauty and wellness space.
Biotechnology firm Celcuity Inc. saw its stock lose 25.65%, closing at $91.42. The drop occurred after the company reported detailed efficacy and safety results from its Phase 3 VIKTORIA-1 trial. The stock traded within a daily range of $89.00 and $99.83 as investors reacted to the new data.
Praxis Precision Medicines, Inc. stock decreased by 23.00% to $258.08. The company announced it granted restricted stock unit awards to new employees. Such actions can sometimes concern investors as they can increase the number of shares on the market, potentially diluting the value of existing shares.
In summary, today’s top losers were heavily influenced by company-specific news. Negative clinical trial updates, disappointing earnings, and corporate actions that may dilute shareholder value were key drivers behind the significant stock price drops in the biotechnology and technology sectors.
